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1. Introduction
Osteoarthritis (OA) is a syndrome characterized by joint pain and 
reduced performance and efficiency in patient [1].  Osteoarthritis 
is one the most common musculoskeletal disorders. According 
to several reports, the incidence of knee osteoarthritis has been 
higher than the incidence of hip osteoarthritis [2-4].  According to 
the World Health Organization report, 18% of women and 6.9% 
of men aged over 60 suffer from osteoarthritis [5].  Osteoarthritis 
treatment is aimed to reduce pain, swelling and disability result-
ing from inflammation and an increased quality of life, since 
there is no decisive cure for it [6].  Some of the solutions used for 
the treatment of this disease include lifestyle changes, medicinal 
treatments, physical treatments, and finally surgery interventions 
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ABSTRACT
Background: Osteoarthritis is a syndrome characterized by joint pain and reduced performance and efficien-
cy in patient.  Thymus daenensis has been used since old times for the treatment of bone and joint deformi-
ties and pain in traditional medicine.
Purpose: This study was conducted to examine traditional usages and pharmacological features of T. daen-
ensis with respect to the effect of the plant in patients with osteoarthritis.
Methods: 120 patients with osteoarthritis were divided into 3 groups.  Patients in each group were treated by 
5% Thymus daenensis gel, 1% diclofenac gel, or placebo for 6 weeks, along with oral celecoxib capsules. 
Patients were assessed in different intervals, based on the VAS score for assessment of pain in the joint and 
different dimensions of WOMAC questionnaire.
Results: Pain level (P < 0.005), stiffness during the day (P < 0.05), morning stiffness (P < 0.05) and physi-
cal performance (P < 0.05) were significantly different among the groups.
Conclusions: Thymus  daenensis gel improves the symptoms in patients equal and without significant differ-
ence than diclofenac group.  It can be argued that its use can produce a satisfactory effect on patients with 
osteoarthritis due to its low cost, easy access, the plant's natively occurring in Iran.
[7-9].  In this regard, medicinal treatments including NSAIDs 
are the main choice for osteoarthritis of the knee [10].  However, 
adverse side effects of medications [11, 12] as well as the likeli-
hood of other diseases cause problems in patients especially in the 
older patients [13, 14].  Studies have indicated increased tendency 
of OA patients to use complementary and alternative treatments 
[15, 16].  These studies show that complementary therapies have 
wide applications for the treatment of chronic diseases in Iran 
[17, 18].  One of the complementary therapies used in OA is us-
ing herbal medicines.  Thymus daenensis is one of the effective 
plants for treatment of osteoarthritis in traditional medicine.  Thy-
mus daenensis fresh leaves and stems have a pleasant smell that 
results from a combination of compounds in oils and extracts of 
this plant.  In vegetative organs of thyme, a compound such as 
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acetate.  After 40 minutes, the absorption of samples was read 
against distilled water (blank) at a wavelength 415 nm.  While 
carrying out the experiment, various concentrations of Rutin were 
prepared.  Absorption of samples was compared with a standard 
curve and total flavonoid content of each extract was stated as mg 
of Rutin equivalent/g dried extract [50].
2.4. Exclusion criteria
Simultaneous severe diseases such as metabolic and gastrointes-
tinal diseases, fluctuation in the dose of the drug during the study, 
the presence of severe infection, allergy to drugs, pregnancy, 
lactation, liver abnormal performance tests, history of fracture or 
surgery on the knee, rheumatoid arthritis and seronegative and se-
ropositive arthropathies, intra-articular injection during 6 weeks, 
simultaneous use of any type of tranquilizer that caused distur-
bance in the result were exclusion criteria of study.  In addition, 
patients who had no willingness in the study were excluded from 
the study.
2.5. Inclusion criteria
Men and women with knee osteoarthritis, diagnosed by an ortho-
pedician according to diagnostic criteria, aged 45-75 years who 
had referred to the Orthopaedic Clinic of Shahrkord University of 
Medical Sciences at least 3 months before the start of the study, 
were included in the study.  They signed an informed consent to 
participate in the study.
2.6. Intervention
The first group received 200 mg capsules celecoxib orally and 
topical gel placebo, the second group received 200 mg capsules 
celecoxib orally on a daily basis and topical 5% thyme gel and 
the third group received 200 mg capsules celecoxib orally and 
topical diclofenac 1% gel 3 times daily for 6 weeks.  Patients 
were instructed that the gel should cover the entire surface of the 
knee.  Topical gel dose for each 5 square centimeters of skin was 
knuckle.  To ensure lack of any additional intervention, patients 
were asked to not massage the knee.
2.7. Effectiveness evaluation
Patient evaluation was performed by means of the Visual Ana-
logue Scale (VAS) to score knee pain at baseline and on the first 
and third days and first, third, and sixth weeks following the inter-
vention.  Besides that, the Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) that is a general and valid 
instrument to examine OA was used as another measurement tool. 
This questionnaire examines three dimensions: pain dimension 
(scored between 0 representing no pain and 4 representing severe 
pain), physical performance (scored between 0 representing no 
problem and 4 representing severe problem) and stiffness (scored 
between 0 representing without stiffness and 4 representing se-
vere stiffness).  The scores of the dimensions were summed and 
the mean value was calculated.  This questionnaire was evaluated 
before treatment and during the first, third days and the first, third 
and sixth weeks after the intervention [21].
2.8. Safety evaluation
All patients were asked to report incidence of allergies or adverse 
phenols, tannins, flavonoids, saponins, and bitter substances are 
found [19-21].  The leaves and flowers of this plant are used as 
antitussive, antispasmodic and anti-flatulence and to treat colds 
[22, 23].  Thymus daenensis has several properties such as anti-
bacterial and antifungal [24-33], and antioxidants [34-42] proper-
ties; it also reduces the fat content [43].  It also has anti-inflam-
matory properties [44-46] and strengthens the immune system of 
the body [47], and it inhibits tyrosinase [48].  According to the 
culture governing the country in higher acceptance of medicinal 
plants and higher acceptance of them by patients and lower side 
effects of these drugs, this study was performed to investigate the 
impacts of topical Thymus daenensis gel in treating and control-
ling symptoms of osteoarthritis.
2. Method
This study has three intervention groups (diclofenac group, herbal 
gel group and placebo group) with the double-blind clinical trial.
2.1. Ethical considerations
The study design is in compliance with the ethical principles of 
Helsinki Declaration.  This study protocol was approved at the 
Behavioral Sciences Ethics Committee of Shahrekord Univer-
sity of Medical Sciences (ethics code IR.SKUMS.REC.1395.54) 
and then in the Iranian clinical trial registration center with code 
IRCT2016112231025N1.  Informed consent form was taken from 
patients participating in the study.
2.2. Plant material and extraction method
Thymus daenensis aerial parts were collected from mountain-
ous areas of the province in the spring of 2016.  Collected Plants 
were identified by Dr. Shirmardi and a herbarium voucher (no. 
248) was deposited at the Herbarium of the Medical Plants Re-
search Center of Shahrekord University of Medical Sciences. 
The powdered plant was extracted by maceration method with 
Ethanol 70% for 48 h.  The obtained extract was passed through 
filter paper.  To remove solvent, the extract was concentrated by 
rotary evaporator at 37°C and lyophilized by freeze dryer.  Then, 
Thymus daenensis gel 5% was formulated in gel base from poly-
mer Carbopol-940 as U.S. Pharmacopeia.  Diclofenac Gel 1% of 
Emad-Darman Pars Company and placebo were filled in same 
aluminum tubes like Thymus daenensis gel.
2.3. Standardization of topical gel
The total phenolic content of aqueous Thymus daenensis extract 
was measured using Folin- Ciocalteu.  To this end, 1 mg/ml crude 
extract reached a volume of 3 ml by addition of distilled water 
and then combined with 0.5 ml Folin-ciocalteu reagent for 10 
minutes.  Next, 4 ml sodium carbonate was added to the resulting 
mixture.  The obtained mixture was stored in the dark for half an 
hour and the optical absorbance was read at 765nm wavelength. 
The total phenolic content was measured by using calibration 
curve, and the results were expressed as the total phenolic content 
(mg of Gallic acid equivalent/g dried extract) [49].  The total fla-
vonoid content Flavonoids were measured according to Liang et 
al. method with some modifications.  In short, 5.0 ml of each ex-
tract solution (0.01 g per 10 ml of methanol at 60°C) was mixed 
with 0.5 ml of 2% aluminum chloride and 3 ml of 5% potassium 
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reactions in follow-up intervals.  A checklist including several 
questions about different organs of the body (such as gastrointes-
tinal problems, nervous system, respiratory system and skin) was 
used.  Potential adverse reactions were investigated by asking the 
participants open-ended questions.
2.9. Sampling, randomization and blinding
Non-probability convenient sampling was used to select samples. 
To this end, the participants were selected from the patients ad-
mitted to the clinic.  To enroll minimum number of people by tak-
ing dropouts into account, 120 people were enrolled in this study 
who were assigned to three groups of 40 each.  Group 1 received 
placebo gel, group 2 received Thymus daenensis extract gel, and 
group 3 received gel containing diclofenac.  To collect data, using 
convenient sampling method, the 120 participants were assigned 
to tube A, tube B, and tube C (each containing 40) and by using 
random sampling method; the patient was asked to select one 
of the Tube A, B, and C.  Then, the intervention was performed. 
Researchers, patients and statistical analysts were blind to the 
content of three types of tubes.
2.10.  Statistical Analysis
The sample size was obtained 35 people considering 95% confi-
dence interval, and test power of 90 percent and study power of 
85 percent.  Considering drop out, 120 were included in the study. 
Data were analyzed using STATA software.  For data analysis, 
inferential and descriptive statistics and duplicate data analysis 
were applied.  Difference in pretest and post-test scores between 
the control and intervention groups were compared.  Pain level, 
morning stiffness of knee joint, improvement in physical perfor-
mance and improvement rate stiffness of knee in studied groups 
were examined.  Repeated measurement and One-way analysis of 
variance (ANOVA) was used to compare quantitative variables 
between the three groups.  Chi-square was used to compare quali-
tative variables.  Bonferroni test was used for multiple compari-
sons.
3. Results
3.1. Standardization of Thymus daenensis gel
The total phenolic content of 1 g of Thymus daenensis gel was 
obtained 5.56 ± 0.98 mg Gallic acid equivalent.  Total flavonoid 
content of 1 g of prepared gel was obtained 0.98 ± 0.06 mg Rutin 
equivalent.
3.2. The baseline characteristics of the study
The process of registration of patients was conducted from June 
to August 2016.  A total of 120 registered patients were divided 
into three groups placebo, diclofenac gel, and herbal gel in a ran-
dom manner as presented Flow Diagrams (Fig. 1).  The average 
age of the patients was 62.75 ± 8.67 in the range of 45-75 years, 
and it was 62.6 ±9.04, 63.83 ± 9.12, and 61.82 ± 7.92 in the pla-
cebo, herbal gel, and diclofenac groups, respectively.  Out of all 
patients studied, 51 (43%) were male and 69 people (57%) were 
female.  Regarding age and gender, no significant difference was 
observed between the groups (p = 0.587).
3.3. Clinical responses
Pain at six intervals had overall reduction both in herbal gel group 
and diclofenac group.  On the day before the intervention and 
the first day after the intervention, significant difference was not 
found among three groups with respect to pain reduction (14.65 ± 
0.77 vs. 13.44 ± 0.72, p = 0.628) and pain reduction was not sig-
nificant, but since the third day, knee pain rate was significantly 
different between diclofenac and placebo, and between thyme and 
placebo since the first week (8.05 ± 0.68 vs. 12.35 ± 0.79, 9.02 
± 0.67 vs. 12.35 ± 0.79, p <0.001) and pain in the diclofenac and 
thyme groups reduced since that time compared to the placebo 
group. no significant difference was observed between diclofenac 
and thyme groups with respect to reduced pain up to the third 
week after the intervention (6.22 ± 0.62 vs. 7.52 ± 0.73, p = 0.796), 
but in the sixth week, a significant difference was observed be-
tween two groups (3.57 ± 0.41 vs. 6.02 ± 3.87, p = 0.02) and rate 
of reduction in pain was more in diclofenac group (Table 1, Fig. 
2).  The pain in the right knee since the third day had a significant 
difference between diclofenac and placebo groups and between 
placebo and thyme groups since the first week and the reduced 
pain was observed.  In addition, up to the third week, not signifi-
cant difference was observed between diclofenac and Thymus 
daenensis groups (1.25 ± 0.13 vs. 1.58 ± 0.13, p = 0.669), but in 
the sixth week, a significant difference was observed between the 
two groups (0.67 ± 0.09 vs. 1.25 ± 0.13, p = 0.01) that this reduc-
tion was more in the diclofenac group (Table 2, Fig. 3).
The pain in the left knee since the third day had a significant 
difference between diclofenac and placebo groups and between 
placebo and thyme groups since the first week and the reduced 
pain was observed.  Besides that, up to the third week, no sig-
nificant difference was observed between diclofenac and Thymus 
daenensis groups (1 ± 0.13 vs. 1.45 ± 0.12, p = 0.587), but in the 
sixth week, a significant difference was noted between the two 
groups (± 0.09 vs. 1.1 ± 0.12, p = 0.04) that this reduction was 
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Analyzed
 (n = 48)
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Withdrawn (n = 1)
Lack of follow -up (n = 0)
Patient decision (n = 0)
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Withdrawn (n = 1)
Lack of follow -up (0)
Patient decision (n = 0)
Excluded (n = 0)
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Lack of follow -up (n = 0)
Patient decision (n = 0)
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Fig. 1 - Flow Diagrams of the Randomized Controlled.
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more in the diclofenac group (Table 3, Fig. 4).  Morning stiffness 
rate declined both in herbal gel and diclofenac groups.  The morn-
ing stiffness had no significant difference among the three groups 
before the intervention and the first day after the intervention (3.02 
Table 2 − Comparison of knee osteoarthritis patients with respect to right knee pain in the 3 groups and 
during 6 follow-up intervals.
Mean ± SE
P value
A B C
Before starting treatment 2.85 ± 0.15 3.05 ± 0.17 2.87 ± 0.18 0.668
First day after treatment 2.83 ± 0.15 2.72 ± 0.16 2.57 ± 0.16 0.528
Third day after treatment 2.73 ± 0.16 2.38 ± 0.15 2.05 ± 0.17   0.013*
First week after treatment 2.57 ± 0.17 1.85 ± 0.14 1.55 ± 0.15   0.000*
Third week after treatment 2.25 ± 0.19 1.58 ± 0.13 1.25 ± 0.13   0.000*
Sixth week after treatment 2.1 ± 0.18 1.25 ± 0.13 0.67 ± 0.09   0.000*
A: Placebo, B: Thymus daenensis group, C: Diclofenac group *P < 0.05.
Table 1 − Comparison of knee osteoarthritis patients with respect to knee pain in the 3 groups and 
during 6 follow-up intervals.
Mean ± SE
P value
Total A B C
Before starting treatment 14.65 ± 0.77 14.05 ± 0.75 15.05 ± 0.77 14.85 ± 0.80     0.628
First day after treatment 13.44 ± 0.72   13.7 ± 0.73   13.5 ± 0.74 13.07 ± 0.69 0.8
Third day after treatment 11.88 ± 0.74   13.3 ± 0.77 11.42 ± 0.72 10.92 ± 0.68     0.05*
First week after treatment     9.8 ± 0.77 12.35 ± 0.79   9.02 ± 0.67   8.05 ± 0.68       0.000*
Third week after treatment   8.21 ± 0.77   10.9 ± 0.84   7.52 ± 0.73   6.22 ± 0.62       0.000*
Sixth week after treatment   6.65 ± 0.77 10.35 ± 0.82   6.02 ± 0.61   3.57 ± 0.41       0.000*
A: Placebo, B: Thymus daenensis group, C: Diclofenac group *P < 0.05.
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Fig. 2 - Comparison of knee osteoarthritis patients with 
respect to knee pain in the 3 groups and during 6 follow-
up intervals.  A: Placebo, B: Thymus daenensis group, C: 
Diclofenac group.
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Fig. 3 - Comparison of knee osteoarthritis patients with 
respect to right knee pain in the 3 groups and during 6 follow-
up intervals.  A: Placebo, B: Thymus daenensis group, C: 
Diclofenac group.
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± 0.14 vs. 2.83 ± 0.14, p = 0.903), but with reduction in morning 
stiffness, since the third day, significant difference was observed 
between diclofenac and placebo groups and between thyme and 
placebo groups since the first week (1.85 ± 0.15 vs. 2.45 ± 0.18, 
1.97 ± 0.13 vs. 2.45 ± 0.18, p <0.01).  In addition, no significant 
difference was observed between diclofenac and Thymus daenen-
sis groups up to the third week after intervention (1.28 ± 0.0.13 
vs. 1.6 ± 0.13, p = 0.822), but in the sixth week, the two groups 
also had significant differences (0.75 ± 0.09 vs. 1.3 ± 0.13, p = 
0.01) and the reduction of morning stiffness in the diclofenac 
group was higher (Table 4, Fig. 5).
Regarding daily stiffness rate, significant difference was not 
found among three groups before intervention and first day after 
intervention (3.01 ± 0.15 vs. 2.81 ± 0.14, p > 0.05), but since the 
third day, significant difference was noted between diclofenac and 
placebo groups(2.22 ± 0.14 vs. 2.75 ± 0.16, p < 0.01), and since 
the first week, significant difference was observed between two 
Table 3 − Comparison of knee osteoarthritis patients with respect to left knee pain in the 3 groups 
during 6 intervals of follow-up.
Mean ± SE
P value
A B C
Before starting treatment 2.62 ± 0.17   2.9 ± 0.16 2.85 ± 0.15 0.424
First day after treatment 2.68 ± 0.17 2.55 ± 0.15 2.53 ± 0.12 0.754
Third day after treatment 2.55 ± 0.17 2.23 ± 0.13 1.97 ± 0.15   0.025*
First week after treatment 2.45 ± 0.17   1.7 ± 0.13 1.58 ± 0.12   0.000*
Third week after treatment 2.13 ± 0.18 1.45 ± 0.12      1 ± 0.13   0.000*
Sixth week after treatment 2.03 ± 0.18   1.1 ± 0.12         ± 0.09   0.000*
A: Placebo, B: Thymus daenensis group, C: Diclofenac group *P < 0.05.
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Fig. 4 - Comparison of knee osteoarthritis patients with 
respect to left knee pain in the 3 groups during 6 intervals of 
follow-up.  A: placebo group, B: Thymus daenensis group, C: 
diclofenac group.
thyme and placebo groups (1.93 ± 0.13 vs. 2.45 ± 0.18, p < 0.01). 
In these groups, pain reduction rate in diclofenac and herbal gel 
groups was more than the placebo group.  In addition, no signifi-
cant difference was observed between diclofenac and Thymus 
daenensis groups up to the third week after intervention (1.28 ± 
0.13 vs. 1.55 ± 0.13, p > 0.05).  However, daily stiffness reduction 
in the diclofenac group was higher in sixth week (0.75 ± 0.09, p < 
0.02) (Table 5, Fig. 6).  Both in the herbal gel group and diclofen-
ac group, physical performance improved.  Regarding physical 
performance in one day before the intervention and the first day 
after the intervention, significant difference was not found among 
the three groups (51.94 ± 2.63 vs. 47.71 ± 15.45, p > 0.05), but 
since the third day, significant difference was noted between 
diclofenac and placebo groups (38.67 ± 2.36 vs. 47 ± 2.56, p < 
0.05) and between thyme and placebo group since the first week 
(32.17 ± 2.24 vs. 44.02 ± 2.78, p < 0.05) and physical perfor-
mance improvement was seen in the group receiving diclofenac 
and the group received herbal gel.  No significant difference was 
observed between two diclofenac and thyme groups with respect 
to physical performance index up to end of the intervention (12.85 
± 1.46 vs. 20.85 ± 2.24, p > 0.05) and in both groups, physical 
performance improvement was equal (Table 6, Fig. 7).
The knee pain rate based on VAS criterion had no significant 
difference before intervention and first day after the intervention 
(7.67 ± 0.33 vs. 7.04 ± 0.31, p > 0.05), but a significant difference 
was noted between placebo and diclofenac groups since the third 
day (7.18 ± 0.33 vs. 5.72 ± 0.28, p < 0.05) and between placebo 
and thyme groups since first week (6.85 ± 0.34 vs. 5.45 ± 0.31, 
p <0.05) and a reduction in pain was observed.  In addition, two 
groups of diclofenac and Thymus daenensis had no significant 
different up to a third week (3.9 ± 0.25 vs. 4.75 ± 0.34, p > 0.05), 
but since the sixth week, the difference was significant between 
the groups (2.78 ± 0.25 vs. 4.1 ± 0.33, p < 0.05) and pain reduc-
tion in the diclofenac group was higher (Table 7, Fig. 8).
Comparison Means and 95% Confidence Intervals (CIs) of 
main outcomes in osteoarthritis patients before and after treatment 
was presented in Table 8.
3.4. Short term tolerance and safety
In the diclofenac group, no topical or systematic adverse effects 
were reported.  In addition, thyme gel was accepted well by pa-
tients and no side effects or adverse physical effect was seen in 
follow- ups.
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4. Discussion
This study examines the effect of Thymus daenensis extract gel 
on knee pain and performance of patients with osteoarthritis.  Our 
study showed that knee pain of patients in the group consuming 
the Thymus daenensis gel significantly decreased so that knee 
pain reduction in thyme group was equal and without significant 
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Fig. 5 - Comparison of knee osteoarthritis patients with 
respect to morning stiffness in the 3 groups during 6 intervals 
of follow-up.  A: Placebo group, B: Thymus daenensis group, 
C: Diclofenac group.
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Fig. 6 - Comparison of knee osteoarthritis patients with 
respect to daily stiffness rate in the 3 groups during 6 intervals 
of follow-up.  A: Placebo group, B: Thymus daenensis group, 
C: Diclofenac group.
Table 4 − Comparison of knee osteoarthritis patients with respect to morning stiffness in the 3 groups 
during 6 intervals of follow-up.
Mean ± SE
P value
A B C
Before starting treatment 2.88 ± 0.15 3.07 ± 0.13 3.12 ± 0.16   0.449
First day after treatment 2.83 ± 0.14 2.83 ± 0.14 2.85 ± 0.15 0.99
Third day after treatment 2.75 ± 0.16 2.38 ± 0.13 2.22 ± 0.14     0.013*
First week after treatment 2.45 ± 0.18 1.97 ± 0.13 1.85 ± 0.15     0.019*
Third week after treatment 2.15 ± 0.18   1.6 ± 0.13 1.28 ± 0.13     0.000*
Sixth week after treatment 2.07 ± 0.17   1.3 ± 0.13 0.75 ± 0.09     0.000*
A: Placebo, B: Thymus daenensis group, C: Diclofenac group *P < 0.05.
Table 5 − Comparison of knee osteoarthritis patients with respect to daily stiffness rate in the 3 groups 
during 6 intervals of follow-up.
Mean ± SE
P value
A B C
Before starting treatment 2.88 ± 0.15 3.03 ± 0.14 3.12 ± 0.16 0.492
First day after treatment 2.83 ± 0.14 2.77 ± 0.15 2.85 ± 0.15 0.934
Third day after treatment 2.75 ± 0.16 2.32 ± 0.13 2.22 ± 0.14   0.027*
First week after treatment 2.45 ± 0.18 1.93 ± 0.13 2.85 ± 0.15   0.014*
Third week after treatment 2.15 ± 0.18 1.55 ± 0.13 1.28 ± 0.13   0.000*
Sixth week after treatment   2.1 ± 0.17 1.25 ± 0.12 0.75 ± 0.09   0.000*
A: Placebo, B: Thymus daenensis group, C: Diclofenac group *P < 0.05.
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Fig. 7 - Comparison of knee osteoarthritis patients with 
respect to physical performance in the 3 groups during 6 
intervals of follow-up.  A: placebo group, B: Thymus daenensis 
group, C: diclofenac group.
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Fig. 8 - Comparison of knee osteoarthritis patients with 
respect to pain rate in the 3 groups during 6 intervals of 
follow-up based on VAS criterion.  A: Placebo group, B: 
Thymus daenensis group, C: Diclofenac group.
Table 6 − Comparison of knee osteoarthritis patients with respect to physical performance in the 3 
groups during 6 intervals of follow-up.
Mean ± SE
P value
Total A B C
Before starting treatment 51.94 ± 2.63 49.57 ± 2.56 53.47 ± 2.54 53.12 ± 2.80 0.514
First day after treatment 47.71 ± 2.44 48.67 ± 2.47 47.72 ± 2.38 47.22 ± 2.55 0.915
Third day after treatment 41.82 ± 2.47 47.02 ± 2.56 40.27 ± 2.32 38.67 ± 2.36   0.038*
First week after treatment 35.17 ± 2.72 44.02 ± 2.78 32.17 ± 2.24 29.87 ± 2.56   0.000*
Third week after treatment 29.43 ± 2.73 39.42 ± 2.96 26.82 ± 2.24 22.55 ± 2.22   0.000*
Sixth week after treatment 23.33 ± 2.72 37.66 ± 2.92 20.85 ± 2.24 12.58 ± 1.46   0.000*
A: Placebo, B: Thymus daenensis group, C: Diclofenac group *P < 0.05.
difference than diclofenac group up to fifth interval or third week 
after intervention.  This result may be due to the characteristics 
of the compounds in the extract of this plant.  For example, there 
is flavonoid compound in this extract and various studies such as 
the study conducted by Asgari et al. have shown that these com-
pounds can reduce the production of arachidonic acid through 
Inhibition of cyclooxygenase and lipoxygenase [46].  Substances 
resulting from the oxidation of arachidonic acid cause pain and 
Table 7 − Comparison of knee osteoarthritis patients with respect to pain rate in the 3 groups during 6 
intervals of follow-up based on VAS criterion.
Mean ± SE
P value
Total A B C
Before starting treatment 7.67 ± 0.33 7.45 ± 0.32 7.88 ± 0.34 7.65 ± 0.33 0.502
First day after treatment 7.04 ± 0.31 7.35 ± 0.32      7 ± 0.32 6.75 ± 0.30 0.317
Third day after treatment 6.41 ± 0.33 7.18 ± 0.33 6.38 ± 0.33 5.72 ± 0.28   0.006*
First week after treatment 5.67 ± 0.34 6.85 ± 0.34 5.45 ± 0.31   4.7 ± 0.28   0.000*
Third week after treatment 4.98 ± 0.35 6.3 ± 0.33 4.75 ± 0.34   3.9 ± 0.25   0.000*
Sixth week after treatment 4.35 ± 0.38 6.18 ± 0.35  4.1 ± 0.33 2.78 ± 0.25   0.000*
A: Placebo, B: Thymus daenensis group, C: Diclofenac group *P < 0.05.
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inflammation in the tissue [51], which in turn will intensify the 
pain.  As a result, flavonoids reduce the pain and inflammation. 
Research has also proven that these compounds can act as ligands 
for opioid receptors and directly exert their analgesic effect [52]. 
Since the effects of oxidative stress and the products of oxidative 
reactions on the creation of osteoarthritis have been proven, anti-
oxidant effects of this plant can be possible causes of the observed 
effects, especially that effects of topical antioxidants containing 
vitamin C and E, selenium, zinc, isoflavones and polyphenols in 
tea in inhibiting oxidative stress processes in the skin have been 
demonstrated [53].  This suggests that topical application of anti-
oxidants can also be effective.  Free radicals of oxygen produced 
in the progression of this disease in joint, indirectly through caus-
ing tissue damage and direct effect on receptors causing pain, 
stimulate the neuroendocrine system [54].
The results obtained in the case of morning stiffness and stiff-
ness of knee joint of patients during the day also indicated that 
there is Thymus daenensis gel reduces the stiffness of the knee 
joint that this reduction was equal to the fifth interval of follow-
up with diclofenac.  In the osteoarthritis disease, created inflam-
mation leads to the creation of joint stiffness that our studied plant 
applies its anti-inflammatory effects through various mechanisms. 
The substances available in the plant extracts such as phenolic 
acids, alkaloids, tannins and saponins might be involved in this 
effect of thyme [20, 21, 55].  For example, in a study conducted 
by Cichocki et al. on the effect of several types of phenolic acids 
on mouse epidermal cells, it was observed that these compounds 
inhibited COX-2 activation.  One of the most important enzymes 
that is involved in the production of inflammatory mediators such 
as prostaglandins, prostacyclin and thromboxane is cyclooxyge-
nase whose inhibition inhibits the inflammatory pathways and 
loss of pain and inflammatory symptoms [56].  Another study by 
Singh et al. on cancerous cells confirmed the effect of isoquino-
line alkaloid on the decreased expression of cyclooxygenase-2 
and reduced production of prostaglandin E2 and prostaglandin E2 
receptors [57].  In the case of physical performance of patients, 
physical activity significantly improved in both groups received 
diclofenac and Thymus daenensis that significant difference was 
not found between two groups to end of the study.  This can be 
due to a reduction in knee pain of patients during daily activities 
and improvement in other symptoms of the disease by reducing 
inflammation.
4.1. Limitations of study
Although the effectiveness of the thyme gel was approved in this 
study, there are some limitations to generalize these results to the 
entire population, including the small size of the population used 
in this study.  Lack of objective criteria for estimating the perfor-
mance of the patients, despite validity and reliability of WOMAC 
Table 8 − Comparison Means and 95% Confidence Intervals (CIs) of outcomes in osteoarthritis patients 
before and after treatment.
Outcome Groups
Initial Final
Mean ± SD CI 95% Mean ± SD CI 95%
Knee Pain
A 14.05 ± 4.75 12.53-15.56   10.35 ± 5.17   8.69-12.00
B 15.05 ± 4.85 13.49-16.60     6.02 ± 3.87 4.78-7.25
C 14.85 ± 5.06 13.23-16.46   3.57 ± 2.6 2.73-4.40
Right Knee Pain
A   2.85 ± 0.97 2.53-3.16       2.1 ± 1.12 1.74-2.45
B 3.05 ± 1.1 2.69-3.40     1.25 ± 0.84 0.98-1.51
C   2.87 ± 1.15 2.50-3.23     0.67 ± 0.57 0.48-.085
Left Knee Pain
A   2.62 ± 1.05 2.28-2.95     2.03 ± 1.12 1.67-2.38
B     2.9 ± 0.98 2.58-3.21       1.1 ± 0.77 0.85-1.34
C   2.85 ± 0.94 2.54-3.15     0.59 ± 0.58   0.4-0.77
Morning Stiffness
A   2.88 ± 0.93 2.58-3.17     2.07 ± 1.09 1.72-2.41
B   3.07 ± 0.85 2.79-3.34       1.3 ± 0.82 1.03-1.56
C   3.12 ± 0.99 2.80-3.43     0.75 ± 0.54 0.57-0.92
Daily Stiffness
A   2.88 ± 0.93 2.58-3.17     2.1 ± 1.1 1.74-2.45
B   3.03 ± 0.89 2.74-3.31     1.25 ± 0.77 1.00-1.49
C   3.12 ± 0.99 2.80-3.43     0.75 ± 0.54 0.57-0.92
Physical Performance
A   49.57 ± 16.21 44.38-54.75     37.66 ± 18.67 31.68-44.63
B   53.47 ± 16.08 48.32-58.61   20.85 ± 14.4 16.24-25.45
C   53.12 ± 17.72 47.45-58.71 12.85 ± 9.2   9.9-15.7
Pain Rate Based on VAS Criterion
A   7.33 ± 2.08 6.66-7.99     6.05 ± 2.18 5.35-6.74
B   7.78 ± 2.16 7.08-8.47   3.68 ± 2.3 2.94-4.41
C   7.65 ± 2.05 6.99-8.30     2.18 ± 1.08 1.83-2.52
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questionnaire was another important limitation of the study.  In 
addition, since the osteoarthritis is a disease with chronic nature, 
the study of variables at an interval after the intervention could 
be a limitation of our study.  With increasing the period of study, 
we can have a better estimate of the impact and acceptability and 
safety of the gel.  In addition, it determines side effects and topi-
cal and general effects resulting from continuous using of the 
considered drug well.
5. Conclusion
Based on the results of this study, the medicinal plant thyme could 
effectively reduce knee pain, morning stiffness and daily stiffness 
in the knees and improve physical performance of patients.  In our 
study, no side effect for this plant was reported, so it can be ar-
gued that its use can produce a satisfactory effect on patients with 
osteoarthritis due to its low cost, easy access, the plant's natively 
occurring in Iran and no problem caused by the consumption of 
chemical drugs.  It is suggested that be done further studies with 
different doses of the plant to be conducted to find the dose that 
has the highest impact and lowest side effect.
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